Peptic ulcer secondary prevention
|
Peptic ulcer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Surgery |
|
Case Studies |
|
2017 ACG Guidelines for Peptic Ulcer Disease |
|
Guidelines for the Indications to Test for, and to Treat, H. pylori Infection |
|
Guidlines for factors that predict the successful eradication when treating H. pylori infection |
|
Guidelines to document H. pylori antimicrobial resistance in the North America |
|
Guidelines for evaluation and testing of H. pylori antibiotic resistance |
|
Guidelines for when to test for treatment success after H. pylori eradication therapy |
|
Guidelines for penicillin allergy in patients with H. pylori infection |
|
Peptic ulcer secondary prevention On the Web |
|
American Roentgen Ray Society Images of Peptic ulcer secondary prevention |
|
Risk calculators and risk factors for Peptic ulcer secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahad Hasan, M.D.[2] Manpreet Kaur, MD [3]
Overview
Screening for peptic ulcer disease is not performed as a population-level primary screening program in low-prevalence regions. Instead, case-finding is recommended in specific high-risk patient populations through a stratified diagnostic approach.[1] The cornerstone of case detection is the Helicobacter pylori test-and-treat strategy combined with esophagogastroduodenoscopy for patients who have alarm features or are aged 60 years or older with new-onset dyspepsia.[1][2]
Screening for Peptic Ulcer
Epidemiology
Peptic ulcer disease occurs at all ages but duodenal ulcers most commonly affect patients between 30 and 55 years, whereas gastric ulcers are more prevalent in patients aged 55 to 70 years.[2]The incidence of duodenal ulcer disease has declined substantially over the past three decades, primarily due to Helicobacter pylori eradication; however, the incidence of gastric ulcers has not declined commensurately, largely because of widespread NSAID and low-dose aspirin use.[2] The following risk factors are associated with the development of peptic ulcer disease:
Risk Factor
- Helicobacter pylori infection: Responsible for ~95% of duodenal ulcers and ~70% of gastric ulcers; infection acquired predominantly in childhood; more prevalent in lower socioeconomic settings, crowded conditions, and early-generation immigrants from endemic regions
- NSAID and aspirin use: risk greater with nonselective NSAIDs, higher doses, and longer duration
- Dual antiplatelet therapy / anticoagulation: Increasing risk in the ageing population; important consideration in bleeding risk stratification
- Tobacco use: associated with recurrence; smoking is a contributing risk factor though not an independent primary cause
- Severe physiological stress: Stress-related mucosal disease occurs in critically ill patients (mechanical ventilation, coagulopathy); distinct from chronic peptic ulcer disease
- Zollinger-Ellison syndrome: associated with multiple, refractory, or atypical location ulcers
- Family history of gastric cancer
- Immigration from high-prevalence regions: Higher H. pylori seroprevalence; cost-effective to screen for H. pylori in this population
Rationale for Screening
Routine population-wide screening for peptic ulcer disease is not recommended by major gastroenterological societies in low-prevalence settings because of low yield in asymptomatic individuals and the cost of esophagogastroduodenoscopy.[2] The United States Preventive Services Task Force (USPSTF) reviewed the topic of screening for Helicobacter pylori in asymptomatic adults but, as of 2025, has not issued a final formal recommendation on routine population-level screening and has noted that its prioritization process precluded moving immediately to evidence review.
Despite the absence of a universal screening recommendation in the general population, targeted case-finding is strongly supported by multiple major guidelines in the following scenarios:
- All patients with active or previous peptic ulcer disease should be tested for Helicobacter pylori, unless prior eradication has been confirmed.[1]
- Patients with uninvestigated dyspepsia who are under 60 years of age and without alarm features should undergo noninvasive Helicobacter pylori testing as the primary diagnostic strategy (test-and-treat approach).[1][2]
- Patients 60 years of age or older with new-onset dyspepsia should be referred directly for esophagogastroduodenoscopy.[1][2]
- Patients of any age with alarm features should proceed directly to esophagogastroduodenoscopy regardless of H. pylori testing status.[1]
- All patients initiating long-term NSAID or daily low-dose aspirin therapy should be tested for Helicobacter pylori and treated if positive, to reduce the synergistic risk of ulceration and gastrointestinal bleeding.[1]
- Patients at increased risk for gastric cancer—including those with atrophic gastritis, gastric intestinal metaplasia, family history of gastric cancer, or immigration from high-incidence regions—should be tested and offered eradication if positive, with consideration for endoscopic surveillance.[1]
Alarm Features Warranting Prompt Endoscopy
The presence of any of the following alarm features in a patient presenting with dyspepsia or epigastric pain mandates prompt esophagogastroduodenoscopy regardless of age:
| Alarm Feature | Clinical Significance |
|---|---|
| Overt gastrointestinal bleeding (hematemesis, melena, or hematochezia) | Suggests bleeding ulcer, gastric cancer, or variceal hemorrhage; requires urgent evaluation |
| Iron deficiency anemia (unexplained) | May indicate chronic occult bleeding from ulcer or gastric cancer |
| Unintentional weight loss | Raises concern for gastric cancer or malignant ulcer |
| Progressive dysphagia or odynophagia | Suggests structural disease including stricture or malignancy |
| Recurrent vomiting | May indicate gastric outlet obstruction |
| Palpable abdominal mass or lymphadenopathy | Raises concern for malignancy |
| Family history of gastrointestinal cancer | Elevated baseline risk for gastric cancer and malignant ulcer |
| Age ≥ 60 years with new-onset dyspepsia | Associated with higher prevalence of significant endoscopic findings and malignancy |
Diagnostic Testing for Helicobacter pylori
Testing for Helicobacter pylori is mandatory in all patients with confirmed or suspected peptic ulcer disease, as well as in those undergoing the test-and-treat strategy for uninvestigated dyspepsia.[1] The choice between noninvasive and invasive testing is guided by whether upper endoscopy is clinically indicated.
Noninvasive Tests (Preferred When Endoscopy Is Not Otherwise Indicated)
| Test | Sensitivity | Specificity | Comments |
|---|---|---|---|
| Urea breath test (¹³C-UBT) | 95–100% | 95–100% | Preferred noninvasive test; highly sensitive and specific; requires fasting for 6 hours; PPIs must be stopped at least 2 weeks before testing; antibiotics stopped for at least 4 weeks before testing to avoid false-negative results |
| Stool antigen test (monoclonal HpSAg) | >95% | >95% | Rapid, reliable, and cost-effective; monoclonal antibody-based preferred over polyclonal; comparable accuracy to UBT; both PPIs (2 weeks) and antibiotics (4 weeks) must be stopped before testing |
| Serology (IgG antibody) | 85–92% | 79–83% | Cannot distinguish active from past infection; not recommended for confirming eradication or for test-of-cure; accuracy not affected by PPIs or antibiotics; may be useful in specific low-resource settings or where other tests are unavailable |
The urea breath test has both sensitivity and specificity of 95–100% for active Helicobacter pylori infection.[3] The stool antigen test (SAT) using monoclonal antibodies has sensitivity and specificity exceeding 95% and is similarly recommended for both diagnosis and confirmation of eradication.[4] Proton pump inhibitors should be discontinued for at least 2 weeks and antibiotics for at least 4 weeks prior to urea breath testing, stool antigen testing, endoscopy, and biopsy to minimize false-negative results.[2]
Invasive Tests (When Endoscopy Is Performed)
When esophagogastroduodenoscopy is undertaken, gastric biopsies should be obtained to evaluate for Helicobacter pylori infection. Invasive biopsy-based methods include the rapid urease test (RUT), histological examination, and microbiological culture. These methods allow direct confirmation of ulcer disease, assessment of bleeding risk via the Forrest classification, and exclusion of malignancy through tissue sampling. Approximately 5–10% of gastric ulcers may harbor malignancy, and biopsy of all gastric ulcers at endoscopy is strongly advised.[5]
Antimicrobial susceptibility testing (culture or molecular PCR) is now recommended by the 2024 ACG guideline when initial eradication therapy fails, to guide salvage therapy in the context of rising resistance rates (clarithromycin and metronidazole resistance now exceeding 30% in North America).[1]
Screening Strategy by Patient Population
| Patient Category | Recommended Screening / Diagnostic Approach | Supporting Guideline |
|---|---|---|
| Age <60 years, dyspepsia, no alarm features | Noninvasive Helicobacter pylori test-and-treat (UBT or SAT); if negative, empirical proton pump inhibitor (PPI) therapy | ACG 2024; AAFP 2023 |
| Age ≥60 years, new-onset dyspepsia | Direct esophagogastroduodenoscopy with biopsy | ACG 2024; AAFP 2023 |
| Any age with alarm features | Prompt esophagogastroduodenoscopy with biopsy | ACG 2024; WGO 2023 |
| Active peptic ulcer disease (confirmed) | Test for Helicobacter pylori (noninvasive or invasive); treat if positive | ACG 2024 |
| Prior history of peptic ulcer (without documented H. pylori cure) | Test for Helicobacter pylori; treat if positive | ACG 2024 |
| Initiating long-term NSAID or daily aspirin therapy | Test for H. pylori; eradicate if positive; consider PPI prophylaxis in high-risk patients | ACG 2024 |
| Patients with low-grade gastric MALT lymphoma or history of early gastric cancer resection | Test for Helicobacter pylori and treat if positive; endoscopic surveillance | ACG 2024 |
| Immigrants or refugees from H. pylori–endemic regions | Consider noninvasive H. pylori testing (SAT preferred for cost-effectiveness); treat if positive | WGO 2023 |
| Patients with atrophic gastritis or gastric intestinal metaplasia | Test for Helicobacter pylori; treat if positive; risk-stratified endoscopic surveillance | ACG 2024 |
| Critically ill patients (mechanical ventilation, coagulopathy) | Stress ulcer prophylaxis with PPI or H₂-receptor antagonist; not H. pylori screening | Institutional protocols |
Post-Treatment Test of Cure
Confirmation of Helicobacter pylori eradication following treatment is recommended in all patients who have been treated for H. pylori infection.[1] Testing should be performed at least 4 weeks after completing antibiotic therapy and at least 2 weeks after cessation of PPI therapy. The urea breath test or stool antigen test (monoclonal) are the preferred modalities for confirming eradication; serology is not suitable for this purpose because antibody titers remain elevated for months to years after eradication.[6]
References
- ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 Chey WD, Howden CW, Moss SF, Morgan DR, Greer KB, Grover S, Shah SC (2024). "ACG Clinical Guideline: Treatment of Helicobacter pylori Infection". Am J Gastroenterol. 119 (9): 1730–1753. doi:10.14309/ajg.0000000000002968. PMID 39626064 Check
|pmid=value (help). - ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 Gisbert JP, Calvet X. Helicobacter Pylori "Test-and-Treat" Strategy for Management of Dyspepsia: A Comprehensive Review. Clin Transl Gastroenterol. 2013 Mar 28;4(3):e32. doi: 10.1038/ctg.2013.3. PMID: 23535826; PMCID: PMC3616453.
- ↑ Sabbagh P, Mohammadnia-Afrouzi M, Javanian M, Babazadeh A, Koppolu V, Vasigala VR, Nouri HR, Ebrahimpour S (2019). "Diagnostic methods for Helicobacter pylori infection: ideals, options, and limitations". Eur J Clin Microbiol Infect Dis. 38 (1): 55–66. doi:10.1007/s10096-018-3414-4. PMID 32632741 Check
|pmid=value (help). - ↑ Leja M, Axon A, Brenner H (2016). "Epidemiology of Helicobacter pylori infection". Helicobacter. 21 (Suppl 1): 3–7. doi:10.1111/hel.12332. PMID 27531537.
- ↑ Selinger CP, Cochrane R, Thanaraj S, Sainsbury A, Subramanian V, Everett S. Gastric ulcers: malignancy yield and risk stratification for follow-up endoscopy. Endosc Int Open. 2016 Jun;4(6):E709-14. doi: 10.1055/s-0042-106959. Epub 2016 May 19. PMID: 27556082; PMCID: PMC4993883.
- ↑ Cortés P, Nelson AD, Bi Y, Stancampiano FF, Murray LP, Pujalte GGA, Gomez V, Harris DM. Treatment Approach of Refractory Helicobacter pylori Infection: A Comprehensive Review. J Prim Care Community Health. 2021 Jan-Dec;12:21501327211014087. doi: 10.1177/21501327211014087. PMID: 33949229; PMCID: PMC8114244.